Ivantis, Inc.
http://www.ivantisinc.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ivantis, Inc.
Alcon Sees Big Opportunity In Glaucoma Surgery; Buys Ivantis For $475M
Ivantis markets the Hydrus Microstent for minimally invasive glaucoma surgery, a field Alcon exited three years ago when it pulled its CyPass from the market
CDER Pilot Program Offers Potential New Pathway For Approval Of Novel Pharmaceutical Excipients
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
Proposed Medicare Code Change Could Affect Reimbursements On Glaucoma Devices
A proposed change to US Medicare billing that would go into effect 1 January might give one manufacturer an edge over its competitor.
Glaukos Lowers 2020 Guidance, Citing 'Competitive Headwind' In MIGS Business
Glaukos Corp. said it expects rising competition in the US microinvasive glaucoma surgery (MIGS) space in 2020 from Ivantis along with surgical procedures.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive